MY157319A - Inhibitors of protein tyrosine kinase activity - Google Patents

Inhibitors of protein tyrosine kinase activity

Info

Publication number
MY157319A
MY157319A MYPI2012004621A MYPI2012004621A MY157319A MY 157319 A MY157319 A MY 157319A MY PI2012004621 A MYPI2012004621 A MY PI2012004621A MY PI2012004621 A MYPI2012004621 A MY PI2012004621A MY 157319 A MY157319 A MY 157319A
Authority
MY
Malaysia
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
inhibitors
compounds
Prior art date
Application number
MYPI2012004621A
Other languages
English (en)
Inventor
Raeppel Stéphane
Vaisburg Arkadii
Raeppel Franck
Claridge Stephen William
Zhan Lijie
Gaudette Frédéric
Mannion Michael
Sato Norifumi
Yuki Yohei
Kishida Masashi
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MY157319A publication Critical patent/MY157319A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2012004621A 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity MY157319A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16

Publications (1)

Publication Number Publication Date
MY157319A true MY157319A (en) 2016-05-31

Family

ID=44788641

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012004621A MY157319A (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Country Status (19)

Country Link
US (3) US8906852B2 (enExample)
EP (2) EP2563795A4 (enExample)
JP (2) JP2013523846A (enExample)
KR (2) KR20130058006A (enExample)
CN (2) CN103025740B (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241422B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6640224A2 (enExample)
EA (2) EA201291055A1 (enExample)
MX (2) MX2012012031A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602954A (enExample)
PH (2) PH12012502073A1 (enExample)
SG (2) SG184883A1 (enExample)
TW (2) TW201204735A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932586A (zh) * 2007-08-29 2010-12-29 梅赛尔基因股份有限公司 蛋白酪氨酸激酶活性的抑制
RU2498988C2 (ru) * 2008-03-05 2013-11-20 Метилджин, Инк. Ингибиторы активности протеинтирозинкиназы
EP2563795A4 (en) * 2010-04-16 2013-10-23 Methylgene Inc Inhibitors of protein intolerance activity
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
EP3200589A4 (en) 2014-09-10 2018-07-25 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
MX2007001216A (es) * 2004-07-30 2007-03-23 Methylgene Inc Inhibidores de la senalizacion del receptor del factor de crecimiento endotelial vascular y del receptor del factor de crecimiento del hepatocito.
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2611370C (en) * 2005-05-20 2014-11-25 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling
MX2007014617A (es) * 2005-05-20 2008-02-11 Methylgene Inc Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
EP2426108B1 (en) * 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
CN101932586A (zh) * 2007-08-29 2010-12-29 梅赛尔基因股份有限公司 蛋白酪氨酸激酶活性的抑制
RU2498988C2 (ru) * 2008-03-05 2013-11-20 Метилджин, Инк. Ингибиторы активности протеинтирозинкиназы
EP2563795A4 (en) * 2010-04-16 2013-10-23 Methylgene Inc Inhibitors of protein intolerance activity
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity

Also Published As

Publication number Publication date
CA2796054A1 (en) 2011-10-20
KR20130058006A (ko) 2013-06-03
EP2563795A4 (en) 2013-10-23
EP2563795A1 (en) 2013-03-06
CN102947315A (zh) 2013-02-27
US8455484B2 (en) 2013-06-04
JP2013523846A (ja) 2013-06-17
EP2563794A1 (en) 2013-03-06
CO6640224A2 (es) 2013-03-22
US20110257175A1 (en) 2011-10-20
PH12012502073A1 (en) 2013-02-11
CN103025740A (zh) 2013-04-03
EA201291055A1 (ru) 2013-09-30
MX2012012031A (es) 2012-12-17
SG184882A1 (en) 2012-11-29
TW201204735A (en) 2012-02-01
WO2011127567A1 (en) 2011-10-20
NZ602948A (en) 2014-09-26
JP2013525286A (ja) 2013-06-20
EP2563794A4 (en) 2013-12-04
US20140315801A1 (en) 2014-10-23
ZA201207482B (en) 2013-09-25
PH12012502070A1 (en) 2015-05-08
MX2012012032A (es) 2012-12-17
ZA201207557B (en) 2013-06-26
US20110257100A1 (en) 2011-10-20
AU2011241422A1 (en) 2012-11-01
UA108878C2 (ru) 2015-06-25
AR080875A1 (es) 2012-05-16
NZ602954A (en) 2014-11-28
CA2796008A1 (en) 2011-10-20
US8906852B2 (en) 2014-12-09
WO2011127565A1 (en) 2011-10-20
AU2011241420B2 (en) 2015-04-16
CO6630193A2 (es) 2013-03-01
AU2011241422B2 (en) 2015-05-07
TW201204734A (en) 2012-02-01
KR20130100234A (ko) 2013-09-10
CN103025740B (zh) 2015-07-01
SG184883A1 (en) 2012-11-29
EA201291052A1 (ru) 2013-04-30
AR080871A1 (es) 2012-05-16

Similar Documents

Publication Publication Date Title
UA101362C2 (en) Protein tyrosine kinase activity inhibitors
MY157319A (en) Inhibitors of protein tyrosine kinase activity
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2007149427A3 (en) Tyrosine kinase inhibitors
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
MY165728A (en) Selective glycosidase inhibitors and uses thereof
EA201300052A1 (ru) [1,8]нафтиридиновые производные
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
WO2012037155A3 (en) Tyrosine kinase inhibitors
NO20090608L (no) Tyrosinkinaseinhibitorer
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
MX2011012524A (es) Inhibidores de proteina cinasa c-met.
PH12014501434A1 (en) Quinoline derivatives as pde10a enzyme inhibitors